Neuland Laboratories' Q2 FY 2025-26 Quarterly Results
- 10 Nov 2025
Result Summary
- Neuland Laboratories Ltd reported a 71.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 63.7%.
- Its expenses for the quarter were up by 36.6% QoQ and 45.5% YoY.
- The net profit increased 596.8% QoQ and increased 194.9% YoY.
- The earnings per share (EPS) of Neuland Laboratories Ltd stood at 75.49 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 516.07 | 300.61 | 315.18 | 71.7% | 63.7% |
Total Expenses | 386.64 | 283.03 | 265.75 | 36.6% | 45.5% |
Profit Before Tax | 129.44 | 17.57 | 49.42 | 636.7% | 161.9% |
Tax | 32.58 | 3.67 | 16.58 | 787.7% | 96.5% |
Profit After Tax | 96.85 | 13.90 | 32.84 | 596.8% | 194.9% |
Earnings Per Share | 75.49 | 10.83 | 25.60 | 597.0% | 194.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Neuland Laboratories Ltd is a pharmaceutical company primarily engaged in the business of manufacturing and marketing active pharmaceutical ingredients (APIs). The company operates in the healthcare sector and is known for its focus on complex and high-quality APIs. Neuland Laboratories also provides contract manufacturing services to various pharmaceutical companies, leveraging its extensive research and development capabilities. As of the latest available data, there are no specific recent developments provided for the company. Understanding the company's core operational focus aids in appreciating its financial performance trends.
Revenue
During the second quarter of the fiscal year 2026 (Q2FY26), Neuland Laboratories Ltd reported a total income of ₹516.07 crores, which represents a significant increase of 71.7% compared to the previous quarter (Q1FY26) where the total income was ₹300.61 crores. When compared to the same period in the previous fiscal year (Q2FY25), the total income increased by 63.7% from ₹315.18 crores. This substantial rise in revenue year-over-year and quarter-over-quarter indicates a strong growth phase for the company.
Profitability
The company demonstrated a notable improvement in profitability during Q2FY26. The profit before tax was recorded at ₹129.44 crores, reflecting a remarkable increase of 636.7% from ₹17.57 crores in Q1FY26 and 161.9% from ₹49.42 crores in Q2FY25. After accounting for taxes, the profit after tax stood at ₹96.85 crores, up by 596.8% from ₹13.90 crores in the previous quarter and 194.9% from ₹32.84 crores in the same quarter last year. Earnings per share (EPS) also saw substantial growth, reaching ₹75.49 in Q2FY26, compared to ₹10.83 in Q1FY26 and ₹25.60 in Q2FY25.
Operating Metrics
The total expenses for Neuland Laboratories Ltd increased to ₹386.64 crores in Q2FY26, up by 36.6% from ₹283.03 crores in Q1FY26 and by 45.5% from ₹265.75 crores in Q2FY25. Despite the rise in expenses, the company managed to achieve significant growth in profitability, as evidenced by the substantial increases in both profit before and after tax. The tax expenses also rose sharply to ₹32.58 crores in Q2FY26 from ₹3.67 crores in the preceding quarter and ₹16.58 crores in the same quarter of the previous year. These metrics indicate an overall expansion in the company’s operations, contributing positively to its financial performance.